Philippe Aftimos, MD · @aftimosp · X·· 7 小时前评分45
正文 · 原文
Analysis by @PTarantinoMD in this #InsightsbyESMO article https://x.com/myesmo/status/2113880715762741474?s=46
#ESMO26 #ESMOAmbassadors
22 浏览 · 0 赞 · 0 转发 · 0 回复
🔹Small improvement in mPFS with pembrolizumab (vs placebo) + chemotherapy in the KN-B49 ph3 study for endocrine resistant, PDL1+ (CPS≥1) HR+/HER2- MBC 🔹Bigger difference in CPS≥10: small numbers and a secondary endpoint 🔹No OS difference #ESMO2 #ESMOAmbassadors @myESMO在 X 查看被引用的帖子
来源：Philippe Aftimos, MD · x.com